Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07728487

Study of AT-587 in Healthy Subjects

This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-587 in healthy subjects

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hepatitis E Digestive System Diseases Hepatitis Hepatitis, Viral, Human Infections Liver Diseases RNA Virus Infections Virus Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Atea Study Site

Edegem, 2650, Belgium

Location status: Recruiting

Location contact

Atea Study Site

CONTACT

About this study

A Phase 1, First-in-Human (FIH), Single-center, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of AT-587 in Healthy Adult Participants

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body mass index (BMI) of 18-29 kg/m2
  • Must agree to use protocol-specified methods of contraception
  • Negative pregnancy test
  • Willing to comply with the study requirements and to provide written informed consent

Exclusion criteria

  • Pregnant or breastfeeding
  • Abuse of alcohol or drugs
  • Use of other investigational drugs within 30 days of dosing
  • Other clinically significant medical conditions

Treatment and study plan

AT-587

Drug

Parallel Assignment

Placebo

Other

Parallel Assignment

Primary outcomes

  1. Proportions (active vs. Placebo) of subjects experiencing treatment-emergent adverse events

    Time frame: Day 1 up to Day 13

Secondary outcomes

  1. Pharmacokinetics (PK) of AT-587 (Cmax)

    Time frame: Day 1 up to Day 13

    Maximum plasma concentration (Cmax)

  2. Pharmacokinetics (PK) of AT-587 (AUC)

    Time frame: Day 1 up to Day 13

    Area under the concentration-time curve (AUC)

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Trials Administrator

CONTACT

[email protected]

888-481-1607

Sponsors and collaborators

Lead sponsor

Atea Pharmaceuticals, Inc.

Industry

Registry information

Official study title

A Phase 1, First-in-Human (FIH), Single-center, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of AT-587 in Healthy Adult Participants

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jul 27, 2026
Registry last updated
Jul 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.